Hillstream Biopharma (NASDAQ:CNTN) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Hillstream Biopharma (NASDAQ:CNTN – Free Report) from a hold rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings downgraded Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Hillstream Biopharma has an average rating of “Sell”.

View Our Latest Report on Hillstream Biopharma

Hillstream Biopharma Price Performance

NASDAQ CNTN opened at $1.64 on Friday. Hillstream Biopharma has a 12 month low of $1.60 and a 12 month high of $5.83. The firm has a market capitalization of $130.68 million, a PE ratio of -3.28 and a beta of 1.49. The company’s 50 day simple moving average is $2.07 and its 200 day simple moving average is $2.62.

Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) last released its earnings results on Monday, November 16th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $3.05 million during the quarter.

Hillstream Biopharma Company Profile

(Get Free Report)

Hillstream BioPharma is a biotechnology company focused on developing experimental treatments for cancer, particularly drug-resistant tumors and cancer stem cells. Its research centers on ferroptosis, a form of cell death that may offer a way to attack cancer cells that are difficult to treat with existing therapies. The company’s development work includes its LION platform, which uses liposomal iron oxide nanoparticles to deliver iron to cancer cells and promote ferroptosis. Hillstream has described HSB-1216 as a potential cancer treatment based on this approach.

See Also

Receive News & Ratings for Hillstream Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.